`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________
`
`EDWARDS LIFESCIENCES CORPORATION, EDWARDS LIFESCIENCES
`LLC, AND EDWARDS LIFESCIENCES AG
`Petitioners
`
`v .
`
`BOSTON SCIENTIFIC SCIMED, INC.
`Patent Owner
`
`____________
`
`Case IPR2017-00060
`Patent 8,992,608
`____________
`
`Before the Honorable NEIL T. POWELL, JAMES A. TARTAL, and ROBERT L.
`KINDER, Administrative Patent Judges.
`
`
`PETITIONERS’ SURREPLY IN OPPOSITION TO PATENT OWNER’S
`MOTION TO EXCLUDE EVIDENCE PURSUANT TO 37 C.F.R. § 42.641
`
`
`
`
`
`1
`This Surreply was authorized by email on December 6, 2017.
`
`
`
`
`
`
`
`
`
`
`In its motion to exclude (“MTE,” Pap. 41, 48), PO improperly includes new
`
`argument and new evidence: (1) attempting to identify a commissure support
`
`element (“CSE”) in Petitioners’ SAPIEN 3 (“S3”) purportedly to show a nexus
`
`between the S3 and ’608; (2) attempting to distinguish statements made during
`
`’608’s prosecution that undercut its nexus argument; and (3) offering a dictionary
`
`definition of “attached” to support an untimely claim construction argument. Use
`
`of a motion to exclude as a substantive surreply is procedurally improper and PO’s
`
`new arguments and new evidence should be disregarded. Kyocera Corp. v.
`
`Softview LLC, IPR2013-7, Pap. 51, 34 (PTAB Mar. 27, 2014) (“A motion to
`
`exclude is neither a substantive sur-reply, nor a proper vehicle for arguing whether
`
`a reply or supporting evidence is of appropriate scope.”); Marvell Semicond., Inc.
`
`v. Int. Vent. I LLC, IPR2014-552, Pap. 65, 2 (PTAB Aug. 13, 2015) (expunging
`
`unauthorized supplemental information cloaked as motion to exclude); Trial Pract.
`
`Guide, 77 Fed. Reg. 48765, 48767 (Aug. 14, 2012) ((“a reply that raises a new
`
`issue or belatedly presents evidence will not be considered and may be returned”).
`
`PO’s motion (Pap. 41 at 7) overstepped by adding further explanation to the
`
`deficient CSE analysis in PO’s Response, which merely circled three areas on
`
`pictures of the S3 with no identification of any components that purportedly
`
`embody a CSE. Response (Pap. 21) at 51; Ex. 2080, Appx. B, Elements 1.2-1.3.
`
`PO’s MTE Reply (Pap. 48) takes its impropriety further—by adding a figure never
`
`
`
`1
`
`
`
`
`
`before cited (Pap. 48 at 4 (pasting Ex. 2046 at 28)), identifying components of S3
`
`as a CSE that it never before mentioned (“a ‘PET layer,’ ‘tissue integral tabs,’ and
`
`sutures” (id. (citing Ex. 2046 at 28))), and then arguing Petitioners ignored this
`
`“evidence.” It is untenable that PO could have “clearly” identified elements and
`
`figures it never before mentioned or cited. Exhibit 2046 was cited only once by PO
`
`for an unrelated issue. Response at 60 (citing Ex. 2046 at 10). PO’s Dr. Brecker
`
`never cited Ex. 2046 or mentioned a PET layer, tissue integral tabs, or sutures.
`
`Also for the first time, PO attempts to distinguish its arguments and
`
`amendments made to obtain the ’608 that require the claimed seal to double over
`
`the frame, adding new arguments and figures to suggest the S3’s discrete, two-skirt
`
`construction is covered by ’608 even though no S3 skirt doubles over the frame.
`
`(Pap. 48 at 2-4). Again, PO’s reply is not the proper vehicle to introduce new
`
`arguments and evidence.
`
`Finally, for the first time, PO submits a dictionary definition of “attached”
`
`(Pap. 48 at 4-5) that is not only unauthorized supplemental information, but also
`
`fails to even support PO’s untimely nexus arguments. Nothing in this new
`
`definition supports PO’s assertion that the BRI of “attached to” permits treating the
`
`integral structure of the S3 frame with a commissure window as artificially
`
`separate structures “attached to” one another.
`
`Petitioners request that PO’s new arguments and evidence be disregarded.
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`
`Dated: December 11, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Gregory S. Cordrey
` Gregory S. Cordrey, Esq. (Reg. No. 44,089)
` Brian P. Egan, Esq. (Reg. No. 54,866)
` Catherine Nyarady, Esq. (Reg. No. 42,042)
` Attorney for Petitioners
`Edwards Lifesciences Corporation,
`Edwards Lifesciences LLC, and
`Edwards Lifesciences AG
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on December
`
`11, 2017, a complete and entire copy of PETITIONERS’ SURREPLY IN
`
`OPPOSITION TO PATENT OWNER’S MOTION TO EXCLUDE
`
`EVIDENCE PURSUANT TO 37 C.F.R. § 42.64 has been served in its entirety
`
`by e-mail on the following addresses of record for Patent Owner:
`
`jennifer.sklenar@apks.com
`
`wallace.wu@apks.com
`
`marc.cohn@apks.com
`
`matthew.wolf@apks.com
`
`edward.han@apks.com
`
`
`
`
`Dated: December 11, 2017
`
`
`
` /s/ Gregory S. Cordrey
`
`
`
`Gregory S. Cordrey, Esq. (Reg. No. 44,089)
`Attorney for Petitioners
`Edwards Lifesciences Corporation,
`Edwards Lifesciences LLC, and
`Edwards Lifesciences AG
`
`
`
`
`
`
`
`
`
`
`4
`
`